Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Children with a History of Multisystem Inflammatory Syndrome in Children: An International Survey.

Hoste, LeviMIS-C researchersSoriano-Arandes, AntoniBuddingh, Emilie PaulineWhittaker, ElizabethBelot, AlexandreUlloa-Gutierrez, RolandoOlbrich, PeterHaerynck, Filomeen2023-05-032023-05-032022-05-19http://hdl.handle.net/10668/22331The optimal severe acute respiratory syndrome coronavirus 2 vaccine strategy for patients with a history of multisystem inflammatory syndrome in children (MIS-C) is unclear. We performed an international survey (32 countries) and found substantial variations in vaccine policies. Respondents did not report relapses of MIS-C or other severe inflammatory side effects after severe acute respiratory syndrome coronavirus 2 vaccination in 273 patients with a history of MIS-C.enCOVID-19MIS-CSARS-CoV-2adverse eventsvaccinationCOVID-19ChildHumansSARS-CoV-2Surveys and QuestionnairesSystemic Inflammatory Response SyndromeVaccinationSevere Acute Respiratory Syndrome Coronavirus 2 Vaccination in Children with a History of Multisystem Inflammatory Syndrome in Children: An International Survey.research article35598642open access10.1016/j.jpeds.2022.05.0281097-6833PMC9119291https://digital.csic.es/bitstream/10261/279790/1/Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20Vaccination%20in%20Children.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119291/pdf